SVIBOR - Papers quoted in CC - project code: 3-01-254
MINISTRY OF SCIENCE AND TECHNOLOGY
Strossmayerov trg 4, HR - 10000 ZAGREB
tel.: +385 1 459 44 44, fax: +385 1 459 44 69
E-mail: ured@znanost.hr
SVIBOR - Collecting Data on Projects in Croatia
Papers quoted in Current Contents on project 3-01-254
Quoted papers: 6
Other papers: 63
Total: 69
Title: The effects of food and metoclopramide on the
pharmacokinetics and side effects of bromocriptine
- Authors:
- Kopitar, Zdravko
- Vrhovac, Božidar (53374)
- Povšić, Lidija
- Plavšić, Franjo (37512)
- Francetić, Igor
- Urbančić, Janez
Journal: Europian Journal of Drug Metabolism and Pharmacokinetics
Volume: 16
Year: 1991
Pages: from 177 to 181
Language: engleski
Title: Pharmacokinetics of Azithromycin After Single Oral Dosing
of Experimental Animals
- Authors:
- Davila, Dušan (96225)
- Kolačny-Babić, Lidija
- Plavšić, Franjo (37512)
Journal: Biopharmacy and Drug Disposition
ISSN: 0142-2782
Volume: 12
Year: 1991
Pages: from 505 to 514
Number of references: 16
Language: engleski
Summary: Azithromycin, a macrolide antibiotic with an enhanced
antimicrobial spectrum, was found to have longer half life than
erythromycin, with marked tissue penetration. The pharmacokinetics of
azithromycin after oral administration were compared with those of
erythromycin in rats (200 mg/kg) and rabbits (80 mg/kg). Concentrations of
azythromicin in liver, lung, kidney, ileum, and brain were higher than
serum concentrations. The slow decline in tissue concentrations was evident
from the biphasic elimination profile. Thus, advantageous pharmacokinetic
properties and the broader antimicrobial spectrum of azythromicin relative
to erythromycin appear to further support its therapeutic potential.
Keywords: azithromycin, erythromycin pharmacokinetics, tissue levels,
Title: Interindividual Changes in Theophylline Pharmacokinetics
Prediction
- Authors:
- Dodig, Slavica
- Plavšić, Franjo (37512)
- Čepelak, Ivana
- Raos, Mladen
- Demirović, Janko
Journal: Acta Pharmaceutica
Number: 1
ISSN: 1330-0075
Volume: 43
Year: 1993
Pages: from 35 to 42
Number of references: 14
Language: engleski
Summary: Using fluorescence polarization immunoassay, theophylline
serum concentration and theophylline pharmacokinetics after a single
intravenous infusion of theophylline were determined in children (n=30)
aged 1-10 years with severe bronchoobstruction. Pharmacokinetic constants
and therapy simulations were calculated on an M 24 Olivetti personal
computer. A dose of 5 mg of teophylline (Aminophylline, Lek) per kg body
mass resulted in therapeutic concentration in only six children, 45 minutes
after the end of infusion. In five children, it persisted after 60 minutes,
but after 300 minutes therapeutic concentration was present in one child
only. According to the results of theophylline therapy simulation in acute
bronchoobstruction, optimal theophylline serum concentration could be
acheived ba a continous intravenous infusion of 2 +/-1 mg/kg*h.
Interindividual differences in theophyline pharmacokinetics necessitate
serum theophyline measurment and individual dosing.
Keywords: teophylline dosage prediction, accute asthma in children,
Title: A study of some enzyme activities associated with
theophylline administration
- Authors:
- Dodig, Slavica
- Čepelak, Ivana
- Demirović, Janko
- Raos, Mladen
- Plavšić, Franjo (37512)
Journal: Acta Pharmaceutica
Number: 1
ISSN: 1330-0075
Volume: 44
Year: 1994
Pages: from 45 to 51
Number of references: 19
Language: engleski
Summary: In this study, rats were given theophylline at a dose of 15
mg/kg body mass (a three-fold therapeutic dose) in order to assess the
possible adverse effects of the drug. Catalytic activities of AST, ALT, LDH
and ALP were measured in the serum and liver of the animals at various time
intervals (45, 60 and 300 min.). The cumulative effect of theophylline,
after a three-day application of the drug, was also studied. Livers of all
studied animals were histopathologically examined. The catalitic activities
of some enzymes were observed to increase as early as after 60 min. in the
animal serum (AST,LDH) and liver (ALP). Pathohystologic examination of the
liver following the cumulative effect of theophylline revealed mild
degenerative alterations. With increased doses of theophylline, udesired
effects of the drug on the liver could be relatively early predicted by the
measurment of catalitic activities of AST and LDH in serum.
Keywords: theophylline, enzyme activities, rats
Title: Bioequivalence of two oral cyclosporine preparations
- Authors:
- Plavšić, Franjo (37512)
- Wolf-Čoporda, Alka (124860)
- Bilušić, Marinko (146276)
- Lovrić, Zdravko (50281)
- Macolić, Viola
- Bubuć-Filipi, Lj
- Vrhovac, Božidar (53374)
Journal: Arzneimittel forschung drug research
Number: 8
ISSN: 0004-4172
Volume: 45
Year: 1995
Pages: from 914 to 918
Number of references: 11
Language: engleski
Summary: A comparison of bioequivalence of two cyclosporine (CAS
59865-13-3) preparations was performed. Ten cyclosporine treated patients
with transplanted kidneys were included. Criteria were successful
transplatation and minimum period from transplantation of at least 6
months. Two months before the experiment, cyclosporine concentrations had
to be in therapeutic range without significant oscillation, and kidney
function stabile. There had to be no signs of cyclosporine nephrotoxicity.
Cyclosporine concentrations in whole blood were measured with a specific
fluoroimmunoassay. Cyclosporine and metabolites concentrations were
measured with radioimmunoassay with non-specific antibody. Mean value and
standard deviations and shape of distribution were calculated for all
numeric data of patients, measured biochemical and other laboratory
parameters. Variance analysis for all measured concentrations according to
sampling times (C0-C12), maximal concentrations C(M), time to maximal
concentrations t(M), times of absorption delaying t(Lag) and area under the
measured concentration curves (AUC) were statistically checked. According
to these data it is concluded that the preparations are bioequivalent; a
time to reach maximum concentration wes slightly shorter for test
preparation (2.5 and 3.2 h, respectively), but not statistically
significant. There are no significant differences between the areas under
the concentration curves (1667 and 1665 ng*h/ml, respectively). After the
calculation of pharmacokinetic parameters of concentration data measured by
a non-specific method a significant difference for areas under
concentration curves was seen (3709 and 4600 ng*h/ml, respectively).
According to these data the relative biological availability of the test
preparation was 80% if the comparison was based on the concentrations
measured with non-specific analytical method.
Keywords: CAS 59865-13-3, Consupren, Cyclosporine, bioequivalence, clinical studies, immunosupressive agent
Title: Pharmacokinetic changes in patients with oedema
- Authors:
- Vrhovac, Božidar (53374)
- Sarapa, Nenad
- Bakran, Ivan (1644)
- Huić, Mirjana
- Macolić, Viola
- Francetić, Igor
- Wolf-Čoporda, Alka (124860)
- Plavšić, Franjo (37512)
Journal: Clinical Pharmacokinetics
Number: 5
ISSN: 0312-5963
Volume: 28
Year: 1995
Pages: from 405 to 417
Number of references: 75
Language: engleski
Summary: The pharmacokinetics of furosemide (frusemide) in patients
with oedema have been relatively well studied, but in many studies it is
unclear whether the disease or the oedema "per se" has the major effect.
The rate of absorption of oral furosemide in patients with oedema was
decreased, but total bioavailability was almost unchanged. The peak serum
concentration (Cmax) and time taken to achieve Cmax were either decreased
or unchanged. Binding of furosemide two plasma proteins is lower in
patients with congestive heart failure (CHF), decompensated liver cirrhosis
(DLC) and nephrotic syndrome, probably as a result of hypoalbuminaemia. The
elimination half-life (t/2) can be unchanged (CHF, DLC) or prolonged
(chronic renal failure:CRF). Plasma and renal clearance are reduced in
patients with CRF and nephrotic syndrome, but are almost unchanged in CHF
and DLC. Disease-induced disorders are mainly responsible for the
alteration of furosemide pharmacokinetics in oedematous conditions, while
the influence of oedema "per se" is probably not clinically relevant. The
pharmacokinetics of digoxin have been studied in a small number of stusies
only. In patients with CHF, considerable interindividual differences have
been found. Because digoxin has a narrow therapeutic window, this drug
should be administered cautiously to oedematous patients. Theophylline has
higher bioavailability in patients with oedema, with significantly higher
Cmax in patients with hepatic cirrhosis and CHF than in healthy volunteers
(29% and 22%, respectively). Furthermore, clearance decreases and t/2
increases in these patients. Angiotensin converting enzyme (ACE) inhibitors
are often administered as prodrugs, and their pharmacokinetic profile could
be influenced by the diseases that accompany oedematous states. However,
the effect of oedema is difficult to discriminate from that of the disease.
Individual ACE inhibitors are affected differently, but importantly the
dosage of perindopril should be reduced in patients with CHF, while for
most other ACE inhibitors the changes in pharmacokinetic parameters are
clinically irrelevant. In conclusion, studies on pharmacokinetic changes in
oedema are limited besides affecting absorption (after oral administration)
and conversion of the prodrug to active form, probably as a result of the
associated disease, oedema has not be proven to cause any clinically
relevant changes in pharmacokinetic parameters for individual drugs.
However, further studies of this aspect of pharmacokinetics are needed.
Title: Individualization of immunosuppresive therapy as
therapeutic problem
- Authors:
- Plavšić, Franjo (37512)
Number: naro
Volume: Među
Year: 1995
Number of references: 123
Language: hrvatski
Information: svibor@znanost.hr
